As Managing Partner of SV Health Investors, Kate Bingham co-leads SV’s biotech franchise, which has a long history of building companies developing transformational new medicines and bringing drugs from discovery to market. Kate’s investments, many of which are examples of SV’s company creation approach to biotech investing, include a wide range of drug discovery and development companies focused on different clinical areas in the UK, EU and US. Her investments have resulted in the launch of eight drugs for the treatment of patients with inflammatory and autoimmune disease and cancer.

In 2021 Kate was awarded a DBE in the Queen’s Birthday Honours for her services as Chair of the UK Vaccine Taskforce, where she led a team of world-class experts with the shared purpose of finding and manufacturing COVID-19 vaccines.

Kate also serves on the Board of the Francis Crick Institute and ARIA. She has a first class degree in biochemistry from the University of Oxford and an MBA from Harvard Business School (Baker Scholar).